PTCT
PTC Therapeutics, Inc. · Healthcare · Biotechnology
Señales de momentum (gestores comparables):
amplitud de titulares +10.0% ·
flujo de acciones +3.1% ·
nuevas posiciones netas +9.1%
· fórmula
Acumulación amplia: acciones en aumento entre más titulares
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q3 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 18.67K | $1.18M | n/a | n/a |
| Q2 2026 | 115 | +8 | 59.02M | $4.80B | +13 | −5 |
| Q1 2026 | 110 | -8 | 65.31M | $4.45B | +9 | −18 |
| Q4 2025 | 117 | 0 | 67.93M | $5.16B | +1 | n/a |
| Q3 2025 | 22 | +2 | 38.04M | $2.33B | +2 | n/a |
| Q2 2025 | 17 | 0 | 34.63M | $1.69B | +1 | −1 |
| Q1 2025 | 14 | +2 | 16.93M | $862.87M | +2 | n/a |
| Q4 2024 | 12 | 0 | 14.84M | $670.12M | n/a | n/a |
| Q3 2024 | 11 | -2 | 14.00M | $519.42M | n/a | −2 |
| Q2 2024 | 13 | n/a | 14.28M | $436.54M | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (pasivo) | 8.29M | -6.3% | $508.70M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (pasivo) | 7.13M | -4.7% | $437.62M | 0.0% | ▼ Trim | 2 | SEC ↗ ×18 |
| 3 | Wellington Management ✦ | 4.92M | +4.8% | $301.86M | 0.1% | ▲ Add | 6 | SEC ↗ ×8 |
| 4 | State Street Global Advisors ✦ (pasivo) | 3.13M | +4.6% | $192.38M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 2.17M | -10.8% | $133.46M | 0.1% | ▼ Trim | 6 | SEC ↗ ×3 |
| 6 | Geode Capital Management ✦ (pasivo) | 1.95M | +0.8% | $119.74M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Citadel Advisors ✦ | 1.73M | +88.0% | $106.23M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Fidelity (FMR) ✦ | 1.61M | -6.2% | $98.91M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 9 | Point72 Asset Management ✦ | 1.22M | Nuevo | $74.91M | 0.2% | New | 1 | SEC ↗ |
| 10 | Millennium Management ✦ | 1.06M | +174.8% | $64.84M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 11 | JPMorgan Chase ✦ | 981.87K | n/a | $60.26M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 12 | Renaissance Technologies ✦ | 927.30K | -3.7% | $56.91M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 13 | Goldman Sachs Group ✦ | 876.41K | n/a | $53.79M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | T. Rowe Price ✦ | 458.33K | +1.0% | $28.13M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 15 | Morgan Stanley ✦ | 419.42K | n/a | $25.74M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 16 | AQR Capital Management ✦ | 331.26K | -38.3% | $20.33M | 0.0% | ▼ Trim | 6 | SEC ↗ ×4 |
| 17 | Arrowstreet Capital ✦ | 323.55K | +851.6% | $19.86M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 18 | Adage Capital Partners ✦ | 291.00K | -52.0% | $17.86M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 19 | Marshall Wace ✦ | 157.74K | -70.7% | $9.68M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 20 | Two Sigma Investments ✦ | 24.34K | -52.1% | $1.49M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 21 | Gotham Asset Management ✦ | 18.06K | -49.3% | $1.11M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 22 | Bridgewater Associates ✦ | 11.94K | Nuevo | $732,635 | 0.0% | New | 1 | SEC ↗ |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Point72 Asset Management | $74.91M | 0.2% |
| Bridgewater Associates | $732,635 | 0.0% |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 348 tenedores, 95.15M acciones, $6.33B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Director · 382 acc. · $22,973
Director · 2.12K acc. · $126,063
Officer · 192 acc. · $12,338
Director · 2.45K acc. · $155,091
Director · 53 acc. · $3,389
Officer · 435 acc. · $27,910
Officer · 1.64K acc. · $104,881
Director · 376 acc. · $25,737
Director · 9.62K acc. · $652,796
Director · 7.01K acc. · $471,854
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología